These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Investigation of a derived adverse outcome pathway (AOP) network for endocrine-mediated perturbations. Ravichandran J; Karthikeyan BS; Samal A Sci Total Environ; 2022 Jun; 826():154112. PubMed ID: 35219661 [TBL] [Abstract][Full Text] [Related]
6. Linking nanomaterial-induced mitochondrial dysfunction to existing adverse outcome pathways for chemicals. Murugadoss S; Vinković Vrček I; Schaffert A; Paparella M; Pem B; Sosnowska A; Stępnik M; Martens M; Willighagen EL; Puzyn T; Roxana Cimpan M; Lemaire F; Mertens B; Dusinska M; Fessard V; Hoet PH ALTEX; 2024 Jan; 41(1):76-90. PubMed ID: 37606097 [TBL] [Abstract][Full Text] [Related]
7. A quantitative weight-of-evidence method for confidence assessment of adverse outcome pathway networks: A case study on chemical-induced liver steatosis. Verhoeven A; van Ertvelde J; Boeckmans J; Gatzios A; Jover R; Lindeman B; Lopez-Soop G; Rodrigues RM; Rapisarda A; Sanz-Serrano J; Stinckens M; Sepehri S; Teunis M; Vinken M; Jiang J; Vanhaecke T Toxicology; 2024 Jun; 505():153814. PubMed ID: 38677583 [TBL] [Abstract][Full Text] [Related]
8. An integrative data-centric approach to derivation and characterization of an adverse outcome pathway network for cadmium-induced toxicity. Sahoo AK; Chivukula N; Ramesh K; Singha J; Marigoudar SR; Sharma KV; Samal A Sci Total Environ; 2024 Apr; 920():170968. PubMed ID: 38367714 [TBL] [Abstract][Full Text] [Related]
9. Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole. Luckert C; Braeuning A; de Sousa G; Durinck S; Katsanou ES; Konstantinidou P; Machera K; Milani ES; Peijnenburg AACM; Rahmani R; Rajkovic A; Rijkers D; Spyropoulou A; Stamou M; Stoopen G; Sturla S; Wollscheid B; Zucchini-Pascal N; Lampen A Chem Res Toxicol; 2018 Aug; 31(8):784-798. PubMed ID: 29995386 [TBL] [Abstract][Full Text] [Related]
10. Optimization of an adverse outcome pathway network on chemical-induced cholestasis using an artificial intelligence-assisted data collection and confidence level quantification approach. van Ertvelde J; Verhoeven A; Maerten A; Cooreman A; Santos Rodrigues BD; Sanz-Serrano J; Mihajlovic M; Tripodi I; Teunis M; Jover R; Luechtefeld T; Vanhaecke T; Jiang J; Vinken M J Biomed Inform; 2023 Sep; 145():104465. PubMed ID: 37541407 [TBL] [Abstract][Full Text] [Related]
11. [Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment]. Yamada T; Ashikaga T; Kojima H; Hirose A Yakugaku Zasshi; 2020; 140(4):481-484. PubMed ID: 32238628 [TBL] [Abstract][Full Text] [Related]
12. Integrative Data Mining Approach: Case Study with Adverse Outcome Pathway Network Leading to Pulmonary Fibrosis. Jeong J; Kim D; Choi J Chem Res Toxicol; 2023 Jun; 36(6):838-847. PubMed ID: 37093963 [TBL] [Abstract][Full Text] [Related]
13. Adverse outcome pathway networks II: Network analytics. Villeneuve DL; Angrish MM; Fortin MC; Katsiadaki I; Leonard M; Margiotta-Casaluci L; Munn S; O'Brien JM; Pollesch NL; Smith LC; Zhang X; Knapen D Environ Toxicol Chem; 2018 Jun; 37(6):1734-1748. PubMed ID: 29492998 [TBL] [Abstract][Full Text] [Related]
14. Mechanism-driven modeling of chemical hepatotoxicity using structural alerts and an in vitro screening assay. Jia X; Wen X; Russo DP; Aleksunes LM; Zhu H J Hazard Mater; 2022 Aug; 436():129193. PubMed ID: 35739723 [TBL] [Abstract][Full Text] [Related]
15. Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale. Halappanavar S; van den Brule S; Nymark P; Gaté L; Seidel C; Valentino S; Zhernovkov V; Høgh Danielsen P; De Vizcaya A; Wolff H; Stöger T; Boyadziev A; Poulsen SS; Sørli JB; Vogel U Part Fibre Toxicol; 2020 May; 17(1):16. PubMed ID: 32450889 [TBL] [Abstract][Full Text] [Related]
16. Mapping DEHP to the adverse outcome pathway network for human female reproductive toxicity. Pogrmic-Majkic K; Samardzija Nenadov D; Tesic B; Fa Nedeljkovic S; Kokai D; Stanic B; Andric N Arch Toxicol; 2022 Oct; 96(10):2799-2813. PubMed ID: 35790550 [TBL] [Abstract][Full Text] [Related]
17. Adverse outcome pathway networks I: Development and applications. Knapen D; Angrish MM; Fortin MC; Katsiadaki I; Leonard M; Margiotta-Casaluci L; Munn S; O'Brien JM; Pollesch N; Smith LC; Zhang X; Villeneuve DL Environ Toxicol Chem; 2018 Jun; 37(6):1723-1733. PubMed ID: 29488651 [TBL] [Abstract][Full Text] [Related]
18. Chemical-induced liver cancer: an adverse outcome pathway perspective. Sanz-Serrano J; Callewaert E; De Boever S; Drees A; Verhoeven A; Vinken M Expert Opin Drug Saf; 2024 Apr; 23(4):425-438. PubMed ID: 38430529 [TBL] [Abstract][Full Text] [Related]
19. A strategy towards the generation of testable adverse outcome pathways for nanomaterials. Murugadoss S; Vinković Vrček I; Pem B; Jagiello K; Judzinska B; Sosnowska A; Martens M; Willighagen EL; Puzyn T; Dusinska M; Cimpan MR; Fessard V; Hoet PH ALTEX; 2021; 38(4):580-594. PubMed ID: 34008034 [TBL] [Abstract][Full Text] [Related]
20. Development of an adverse outcome pathway from drug-mediated bile salt export pump inhibition to cholestatic liver injury. Vinken M; Landesmann B; Goumenou M; Vinken S; Shah I; Jaeschke H; Willett C; Whelan M; Rogiers V Toxicol Sci; 2013 Nov; 136(1):97-106. PubMed ID: 23945500 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]